Member Theresa Carnegie was quoted by Bloomberg Law in an article about the Trump Administration’s new drug-pricing models, which aim to align Medicare drug prices with lower international prices. The article notes that the pharmaceutical industry is raising legal questions about whether CMS has the authority to implement the two new pricing demonstrations.

Theresa observes that that proposition could be a tipping point for lawsuits as some drugmakers may argue the "programs exceed the demonstration and waiver authority granted to the Center for Medicare & Medicaid Innovation.

Source

Bloomberg Law